About Us
Meet the Team
Conditions & Procedures
Patient Center
Education & Training
Research
Thoracic Oncology Clinical Trials
Program Labs
- Thoracic Oncology Lab
- Kratz Lab
- Thoracic ERAS Program
- Clincial Trials
News & Events
Matthew A. Gubens, M.D., M.S.
- Associate Clinical Professor of Medicine
- Division of Hematology/Oncology
- Department of Medicine
Contact Information
Education
- 1993-1997, Yale University, New Haven, CT, BA, Ethics, Politics and Economics
- 1998-2000, Harvard School of Public Health and Management, MS, Health Policy and Management
- 2000-2005, Stanford University School of Medicine, MD
Clinical Expertise
- Bronchioloalveolar Carcinoma (BAC)
- Chest Wall Tumors
- Lung Carcinoid Tumors
- Lung Metastases
- Malignant Mesothelioma
- Mediastinal Tumors
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Thymoma & Thymic Carcinoma
Biography
Matthew Gubens, M.D., M.S. is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, and are actively working to translate laboratory-based findings to the clinic, especially for patients with epidermal growth factor receptor (EGFR) mutations, who are often young non-smokers.
Dr. Gubens earned his medical degree at Stanford, completed an internal medicine residency at UCSF and then a medical oncology fellowship at Stanford. He also holds an MS degree in Health Policy and Management from Harvard School of Public Health. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Thymic Malignancy Interest Group and the American College of Physicians.
Clinical Trials
Data provided by UCSF Profiles, powered by CTSI
- Study ID: NCT04061590Start Date: Dec 2019Estimated Completion Date: Apr 2022Condition(s): Lung Non-Small Cell Carcinoma, Lung Cancer
- Study ID: NCT04185883Start Date: Dec 2019Estimated Completion Date: Nov 2026Condition(s): Solid Tumor, Sarcoma
- Study ID: NCT04077463Start Date: Sep 2019Estimated Completion Date: Dec 2024Condition(s): Lung Cancer, Non-Small Cell Lung Cancer
- Study ID: NCT03710876Start Date: Jan 2019Estimated Completion Date: Nov 2024Condition(s): Mesothelioma
- Study ID: NCT02823990Start Date: Dec 2016Estimated Completion Date: Oct 2020Condition(s): Lung Cancer, Non-Small Cell Lung Cancer
- Study ID: NCT02578680Start Date: Jan 2016Estimated Completion Date: Mar 2021Condition(s): Lung Cancer
- Study ID: NCT02039674Start Date: Feb 2014Estimated Completion Date: Oct 2021Condition(s): Lung Cancer, Non-Small Cell Lung Cancer, Immunotherapy
- Study ID: NCT01905657Start Date: Aug 2013Estimated Completion Date: Oct 2020Condition(s): Lung Cancer, Non-Small Cell Lung Cancer
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 61
Data provided by UCSF Profiles, powered by CTSI
- Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med. 2023 Jul 10. View in PubMed
- Middha P, Thummalapalli R, Betti MJ, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Genetic prediction of colitis in non-small cell lung cancer patients on immune checkpoint inhibitor therapy. medRxiv. 2023 May 16. View in PubMed
- Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, Park HS, Rodrigues G, Wolf A, Simone CB. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol. 2023 07 01; 9(7):971-980. View in PubMed
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023 04; 21(4):340-350. View in PubMed
- Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart S, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Madani MH, Digumarthy SR, McCoach C, Piotrowska Z, Neal JW, Riess JW. Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clin Res Rep. 2023 Mar; 4(3):100459. View in PubMed
- View All Publications